best peptides for erectile dysfunction FAQ

Your erectile dysfunction is not testosterone-dependent. The HPG axis responded correctly, but peripheral vascular or smooth muscle function remains impaired. This pattern is common in men with diabetes or atherosclerotic disease where nitric oxide signaling is disrupted independent of hormone levels. Combine Kisspeptin-10 with a PDE5 inhibitor to address both hormonal and vascular components, or discontinue Kisspeptin-10 and rely on PDE5 inhibition alone if testosterone normalization provides no subjective benefit.

Increase the dose to 2.0mg subcutaneous for the second trial. Phase 3 data showed that 18% of non-responders at 1.75mg achieved response at 2.0mg. If two doses at 2.0mg produce no measurable effect, PT-141 is unlikely to work for you because your dysfunction pattern is probably vascular rather than central. Switch to Kisspeptin-10 evaluation if low testosterone is suspected, or trial PDE5 inhibitors if vascular insufficiency is the likely cause.

Reduce the dose to 0.25mg and pre-medicate with 25mg meclizine (Dramamine) 30 minutes before injection. This protocol reduced nausea from 60% to 22% in a 2021 tolerability study. Titrate the Melanotan II dose upward by 0.25mg every third administration until you reach minimal effective dose. If nausea persists at 0.5mg despite antiemetic pre-treatment, discontinue Melanotan II and switch to PT-141, which produces nausea in only 40% of users and at lower severity.

Nausea occurs in approximately 30–40% of men during initial PT-141 or melanotan II administration due to melanocortin receptor activation in the brainstem area postrema, which regulates nausea and emesis. Dose reduction (starting at 0.5mg for melanotan II or 1mg for PT-141) and slow titration over 2–3 administrations typically resolves symptoms as central melanocortin receptors downregulate. Flushing results from peripheral vasodilation and usually resolves within 60–90 minutes. Pretreatment with an H2-receptor antagonist (famotidine 20mg) may reduce flushing intensity without impairing erectile response.

Kisspeptin-10 stimulates endogenous LH and FSH release without suppressing the hypothalamic-pituitary axis, meaning it does not cause testicular atrophy or spermatogenic shutdown the way exogenous testosterone does. This makes kisspeptin-10 the only hormonal intervention that can restore testosterone levels while preserving or even enhancing fertility. Exogenous testosterone replacement would suppress FSH and halt spermatogenesis within 8–12 weeks, making it unsuitable for men planning conception.

Combination protocols may be appropriate. Kisspeptin-10 to restore testosterone production and PT-141 to address central arousal deficits. The two peptides act on distinct pathways and do not compete or interfere mechanistically. Clinical trials have not formally evaluated this combination, but the pharmacological rationale is sound: normalize hormonal support first (kisspeptin-10 administered daily for 2–4 weeks to restore baseline testosterone), then address residual arousal or performance anxiety with PT-141 as needed before sexual activity.

Consider PT-141 if the patient has normal nocturnal erections (indicating intact vascular capacity) but impaired arousal or performance anxiety during partnered activity. PT-141 targets central arousal pathways that sildenafil does not address. If the patient has diabetes, hypertension, or documented endothelial dysfunction, VIP or melanotan II may address peripheral vascular failure points beyond nitric oxide pathways. Kisspeptin-10 should be evaluated only if serum testosterone is below 350 ng/dL and the patient shows low LH levels, indicating hypothalamic suppression rather than primary testicular failure.